E3 ubiquitin ligase Pellino1 suppresses acinar cell necroptosis and alleviates severe acute pancreatitis by promoting ubiquitin-dependent receptor-interacting protein kinase 3 (RIP3) degradation.

IF 7.7 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Jiatong Chen, Zhiwei Huang, Pei Jing, Hao Shi, Shenglu Liu, Lu Feng, Yang Long, Mingxin Ye, Wenguang Fu, Peng Tan
{"title":"E3 ubiquitin ligase Pellino1 suppresses acinar cell necroptosis and alleviates severe acute pancreatitis by promoting ubiquitin-dependent receptor-interacting protein kinase 3 (RIP3) degradation.","authors":"Jiatong Chen, Zhiwei Huang, Pei Jing, Hao Shi, Shenglu Liu, Lu Feng, Yang Long, Mingxin Ye, Wenguang Fu, Peng Tan","doi":"10.1111/bph.70175","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Severe acute pancreatitis (SAP) is a critical abdominal condition with high mortality rates. The activation of necroptosis in acinar cells is an critical mechanism for SAP. Pellino1 (PELI1), as an E3 ubiquitin ligase, is involved in pathogenic mechanisms in various diseases. Its ubiquitination function also can regulate necroptosis. However, in SAP, there is a lack of research on upstream regulatory mechanisms and small molecule-targeted drug therapy of necroptosis. Therefore, it is of great significance to study the specific mechanism of PELI1 regulating necroptosis in SAP.</p><p><strong>Experimental approach: </strong>We designed animals and cells with overexpression and knockdown of PELI1 to study the role of PELI1 in SAP, detect the ubiquitination regulatory mechanism of PELI1 on necroptosis and explore the therapeutic effect of GSK-872 in SAP models in vitro and in vivo.</p><p><strong>Key results: </strong>We revealed that PELI1 expression was significantly down-regulated in SAP mouse models and in vitro SAP cell models. Additionally, the overexpression experiments at the cellular and animal levels confirmed the protective effect of PELI1 in SAP and its negative regulatory effect on necroptosis. Mechanistically, our investigation identified that PELI1 degraded RIP3 through K48-linked ubiquitination to inhibit necroptosis, and thereby promote acinar cell activity. Furthermore, we found that GSK-872 effectively inhibited necroptosis and alleviated pancreatic damage in SAP.</p><p><strong>Conclusions and implications: </strong>Our findings highlight the protective role of PELI1-mediated ubiquitination-dependent proteasomal degradation of RIP3 in SAP and propose pharmacological inhibition of RIP3 as a promising strategy to combat SAP.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70175","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Severe acute pancreatitis (SAP) is a critical abdominal condition with high mortality rates. The activation of necroptosis in acinar cells is an critical mechanism for SAP. Pellino1 (PELI1), as an E3 ubiquitin ligase, is involved in pathogenic mechanisms in various diseases. Its ubiquitination function also can regulate necroptosis. However, in SAP, there is a lack of research on upstream regulatory mechanisms and small molecule-targeted drug therapy of necroptosis. Therefore, it is of great significance to study the specific mechanism of PELI1 regulating necroptosis in SAP.

Experimental approach: We designed animals and cells with overexpression and knockdown of PELI1 to study the role of PELI1 in SAP, detect the ubiquitination regulatory mechanism of PELI1 on necroptosis and explore the therapeutic effect of GSK-872 in SAP models in vitro and in vivo.

Key results: We revealed that PELI1 expression was significantly down-regulated in SAP mouse models and in vitro SAP cell models. Additionally, the overexpression experiments at the cellular and animal levels confirmed the protective effect of PELI1 in SAP and its negative regulatory effect on necroptosis. Mechanistically, our investigation identified that PELI1 degraded RIP3 through K48-linked ubiquitination to inhibit necroptosis, and thereby promote acinar cell activity. Furthermore, we found that GSK-872 effectively inhibited necroptosis and alleviated pancreatic damage in SAP.

Conclusions and implications: Our findings highlight the protective role of PELI1-mediated ubiquitination-dependent proteasomal degradation of RIP3 in SAP and propose pharmacological inhibition of RIP3 as a promising strategy to combat SAP.

E3泛素连接酶Pellino1通过促进泛素依赖性受体相互作用蛋白激酶3 (RIP3)降解抑制腺泡细胞坏死,缓解重症急性胰腺炎。
背景与目的:重症急性胰腺炎(SAP)是一种死亡率高的重症腹腔疾病。腺泡细胞坏死坏死的激活是SAP发生的重要机制。Pellino1 (PELI1)作为E3泛素连接酶,参与多种疾病的发病机制。其泛素化功能也可调节坏死坏死。然而,在SAP中,缺乏对坏死下垂上游调控机制和小分子靶向药物治疗的研究。因此,研究PELI1在SAP中调控坏死性坏死的具体机制具有重要意义。实验方法:通过设计PELI1过表达和敲低的动物和细胞,研究PELI1在SAP中的作用,检测PELI1对坏死性坏死的泛素化调控机制,探讨GSK-872对SAP模型的体内外治疗作用。关键结果:我们发现在SAP小鼠模型和体外SAP细胞模型中,PELI1的表达显著下调。此外,在细胞和动物水平上的过表达实验证实了PELI1在SAP中的保护作用和对坏死下垂的负调控作用。在机制上,我们的研究发现PELI1通过k48连接的泛素化降解RIP3来抑制坏死坏死,从而促进腺泡细胞的活性。此外,我们发现GSK-872有效地抑制了SAP患者的坏死性坏死,减轻了胰腺损伤。结论和意义:我们的研究结果强调了peli1介导的泛素化依赖的RIP3蛋白酶体降解在SAP中的保护作用,并提出了RIP3的药理抑制是一种有希望的对抗SAP的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信